We know that myeloproliferative neoplasms may occasionally run in families, but what we don’t know is why. The Fleischman Lab, headed by Dr. Angela Fleischman, MD. PhD. in Irvine, CA is seeking to answer that question. Through the MPN Family Study, Dr. Fleischman is working to identify why some families are more likely to get… Read More »THE MPN FAMILIAL STUDY
Exciting drug development news for Myelofibrosis patients, aimed at people whose disease had progressed or did not see an adequate response while on Ruxolitinib. A researcher at Mt. Sinai in this video discusses observations from their clinical trial with the drug CPI-0610. Investigators saw improvement in anemia as well as improvement in bone marrow in some… Read More »CPI-0610 DEMONSTRATES ACTIVITY IN MF PATIENTS AFTER RUXOLITINIB FAILURE
The American Society of Hematology presented Emmanuelle Passegué, Ph.D., of Columbia University Irving Medical Center in New York City with the 2019 William Dameshek Prize for her outstanding contribution to the field of hematology. “Dr. Passegué, director of Columbia Stem Cell Initiative at Columbia University Irving Medical Center and Alumni Professor of Genetics and Development at… Read More »ASH AWARDS THE 2019 WILLIAM DAMESHEK PRIZE
The approval of Inrebic (fedratinib) for myelofibrosis is the first FDA-approval of a new therapy for myelproliferative neoplasms in nearly a decade. We at the MPN Research Foundation are thrilled to see more options for people living with myelfobrosis who have long suffered with few options for relief. We hope this approval ushers in a… Read More »FEDRATINIB APPROVED FOR MYELOFIBROSIS!
In an article published by CURE Today, MPN Research Foundation’s Executive Director, Michelle Woehrle, sat down with Kristie L. Kahl, to discuss the FDA’s approval of new Myelofibrosis drug Inrebic (fedratinib), the first approved drug for the disease in nearly a decade. “We at the MPN Research Foundation are thrilled to see more options for people living with myelofibrosis… Read More »MPNRF QUOTED IN CURE TODAY MAGAZINE
Myeloproliferative neoplasms (MPN) patient advocacy organizations are working together across borders to ensure that people living with an MPN (polycythemia vera, essential thrombocythemia and myelofibrosis) will have their treatment needs met by partnering with one another. These organizations are driven by the need to ensure a better understanding about the origins of MPN in hopes… Read More »RESEARCH INTO RARE BLOOD CANCERS CALLED MYELOPROLIFERATIVE NEOPLASMS GOES GLOBAL
Actuate Therapeutics Inc. is recruiting patients for Actuate 1901: 9-ING-41, a phase 2 study that will study its efficacy in patients with advanced MF. Official Title: Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, as a Single Agent or Combined With Ruxolitinib, in Patients With Myelofibrosis Detailed Description: 9-ING-41 is a first-in-class, intravenously administered,… Read More »NEW CLINICAL TRIAL AVAILABLE FOR MYELOFIBROSIS PATIENTS
While there were no major breakthroughs at this year’s ASH, there was a high level of clinical activity reported, both in terms of new therapies advancing through clinical trials as well as new drug mechanisms entering trials or in preclinical development. Furthermore, we continue to see new studies to better understand the factors leading to… Read More »2019 ASH MEETING REPORT
The MPN Heroes Celebration Event held annually at ASH is an opportunity to recognize the individuals and organizations who work hard on behalf of the MPN community and make a difference in the lives of patients living with PV, ET, and MF. Each year at this event, recipients of the MPN Heroes Recognition Program are… Read More »MICHELE COURI IS HONORED AS AN MPN HERO
With your support, The MPN Research Foundation has aided in research that has resulted in a better understanding of Polycythemia Vera, Essential Thrombocythemia, and Myelofibrosis. A recent article titled “JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML” was published in the Journal of Experimental Medicine and is partially funded by MPNRF and our supporters through the Interferon Initiative. An… Read More »The Interferon Initiative makes news
